What are the common adverse reactions of brigatinib/brigatinib?

Brigatinib/Brigatinib (Brigatinib) is an oral second-generation ALK tyrosine kinase inhibitor that is widely used to treat patients with non-small cell lung cancer (NSCLC) carrying ALK gene rearrangements, especially for patients who are resistant to crizotinib. Although brigatinib has shown strong efficacy in prolonging survival and controlling tumor progression, it may still be accompanied by certain adverse reactions during the treatment process, and patients and doctors need to remain highly vigilant about this.

The most common adverse reactions of brigatinib are mainly concentrated in the digestive tract, musculoskeletal system and respiratory system. Among them, nausea, vomiting, diarrhea and loss of appetite are common gastrointestinal reactions. Although most of them are mild to moderate, their persistence may affect the patient's medication compliance. For some patients, these symptoms can be alleviated by adjusting their diet and using antiemetic drugs. Muscle weakness or elevated creatine kinase are also common laboratory index changes, especially in the early stages of treatment, which need to be monitored by regularly testing creatine kinase (CK) levels.

In addition, one of the more special adverse reactions of brigatinib is lung-related discomfort. Some patients may experience interstitial lung disease-like symptoms in the early stages of treatment, such as cough, shortness of breath, hypoxia and even pneumonia-like changes. Although the incidence of these conditions is not high, due to their potential seriousness, sufficient attention needs to be paid. It is usually recommended to closely monitor lung function changes in the early stages of treatment and promptly discontinue the drug or adjust the dose when abnormal symptoms occur.

Visual disturbances, hypertension, and bradycardia are other adverse reactions that may occur with long-term use of brigatinib. Visual changes may manifest as blurred vision, light and shadow interference, etc. Although most of them are mild, their persistence may affect the quality of life. Elevated blood pressure requires combined antihypertensive treatment to control the risk, while bradycardia usually requires individualized assessment in conjunction with ECG monitoring.

Reference materials:https://www.alunbrig.com/